Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Diabetic Ulcers Treatment Market

Diabetic Ulcers Treatment Market Trends

Report ID: GMI6078
Published Date: Jun 2023
Report Format: PDF

Download Free Sample

Diabetic Ulcers Treatment Market Trends

Increasing number of diabetic patients across the globe positively influencing the diabetic ulcers treatment market growth. High incidence of diabetic ulcers in these patients increases the demand for treatment. Several factors such as sedentary lifestyle and lack of physical activity contribute to obesity, thereby increases the risk of developing diabetes. Similarly, poor dietary choices, including excessive consumption of processed foods, sugary beverages, and high-calorie meals, lead to weight gain and the development of diabetes.

For instance, as per the International Diabetes Federation, in 2021, approximately 537 million adults had diabetes and the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. Such high numbers of diabetic patients will contribute significantly towards the overall business expansion.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of diabetic ulcers treatment reached USD 9.3 billion in 2022 and will grow at over CAGR 5.8% CAGR from 2023 to 2032 attributed to the rise in the diabetic population continues.

The foot ulcer segment dominated the diabetic ulcers treatment market in 2022 with a industry share of 88.8%, owing to high incidence of diabetic foot ulcers amongst diabetic patients.

North America diabetic ulcers treatment industry accounted for over 38.3% revenue share in 2022 and will continue to grow over 2023-2032, due to rising diabetes rate in the region due to factors such as sedentary lifestyles, unhealthy eating habits, and an aging population.

B. Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis Holdings Inc., Derma Sciences Inc., Integra LifeSciences, Hill Rom Holdings Inc., Mölnlycke Health Care AB, Coloplast Corp, Cardinal Health, ConvaTec Group Plc, Tissue Regenix, 3M Healthcare, and Medline Industries, Inc. among others.